Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "Vice-President"

904 News Found

Lilly to establish new global capability centre in Hyderabad
News | January 09, 2025

Lilly to establish new global capability centre in Hyderabad

Lilly plans to hire approximately more than 1,000 new highly-skilled team members


Zydus Lifesciences appoints Vikram Shukla as President - Parenteral Operations
People | January 06, 2025

Zydus Lifesciences appoints Vikram Shukla as President - Parenteral Operations

He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables


Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business
People | January 03, 2025

Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business

Prithwish has close to 28 years of experience in a Commercial role


Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)
People | January 02, 2025

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience


Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
News | January 01, 2025

Anthem Biosciences files DRHP for Rs. 3,395 crore IPO

Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients


Thyrocare secures NABL accreditation for its Labs
News | December 27, 2024

Thyrocare secures NABL accreditation for its Labs

Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation


USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Drug Approval | December 21, 2024

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the


Merck to discontinue KeyVibe and Keyform clinical trials
Diagnostic Center | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program


Merck announces FDA acceptance of biologics license application for Clesrovimab
Drug Approval | December 17, 2024

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season


Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Drug Approval | December 14, 2024

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months